Related Experiment Video
Updated: May 26, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Frontotemporal dementia - features, diagnosis and management.
Daniel K Y Chan1, Sharon Reutens, Dennis K W Liu
1University of New South Wales, Sydney, New South Wales, Australia. daniel.chan@sswahs.nsw.gov.au
Australian Family Physician
|December 8, 2011
Summary
Frontotemporal dementia (FTD) is a common cause of dementia in middle-aged adults, leading to significant health problems and increased mortality. Advances in genetics are improving our understanding of FTD pathophysiology.
Area of Science:
- Neurology
- Neuroscience
- Genetics
Background:
- Frontotemporal dementia (FTD) is a prevalent form of dementia in the 45-65 age group.
- FTD significantly increases morbidity and mortality risk.
Purpose of the Study:
- To provide an overview of frontal lobe function pathophysiology.
- To discuss the genetics of frontotemporal dementia.
- To summarize clinical features, diagnosis, and management of FTD.
Main Methods:
- Review of current literature on FTD.
- Analysis of genetic factors contributing to FTD.
- Synthesis of clinical presentation and diagnostic criteria.
Main Results:
- Genetic advances have enhanced understanding of FTD pathophysiology.
- Diagnosis relies on clinical features and neuropsychological testing, supported by imaging.
- Behavioral management is central to FTD care.
Conclusions:
- Despite early descriptions, genetics has deepened FTD understanding.
- FTD diagnosis is primarily clinical, aided by neuropsychological tests.
- Management challenges persist, with limited evidence for pharmacological interventions.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...